Inhalt drucken


How will the strained Switzerland – EU relations affect Swiss life science ventures?

Technologiepark Basel AG

Relations between Switzerland and the European Union have considerably cooled during the past months. The first to suffer individual, adverse consequences in terms of market access is the medtech sector. However, other life science ventures (biotech, pharma) may also be affected in the near future. The event will provide an overview of what to watch out for.

The webinar will include a Q&A part with the opportunity to discuss individual situations and questions. Please submit your questions beforehand here to allow the speakers to prepare.


When: Thursday, 29.04.2021, 13:00 – 14.15
Where: Online
Language: English


Participation is free, however registration is required before April 29, 2021, 12pm. You will receive the link to the event after your registration has been confirmed. Follow this link to register.



13:00 Welcome
Mitja Messerli, Marketing & Stakeholder Relations Technologiepark Basel

13.05 How will the strained Switzerland – relation affect Swiss life science ventures?
Remus Muresan, Dr. iur., owner of Muresan | Legal

13.45 Closing
Heike Bihlmann, Swiss Biotech Association, Liason Basel

13.50 Q&A

14.15 End


Datum & Zeit

Do. 29. April 2021

13:00 - 14:15 Uhr




Technologiepark Basel AG
Mitja Messerli